Halozyme Therapeutics | HALO - Чистый доход





Чистый доход Изменить Дата
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 1.82B 486M 2026-03
Baxter International USD -15M 1.11B 2026-03
Cara Therapeutics USD -5.53M 621K 2025-09
Cytokinetics USD -206.03M 23M 2026-03
DBV Technologies USD -33.16M 8.71M 2025-09
Eli Lilly USD 7.4B 760M 2026-03
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
MannKind USD -15.95M 23.93M 2025-12
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Nektar Therapeutics USD -36.08M 978K 2025-12
Pfizer USD 2.69B 4.34B 2026-03
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
United Therapeutics USD 274.9M 89.4M 2026-03
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12